OrganiGram Net Receivables from 2010 to 2026

OGI Stock  USD 1.29  0.01  0.78%   
OrganiGram Holdings' Net Receivables is increasing with slightly volatile movements from year to year. Net Receivables is estimated to finish at about 78.3 M this year. For the period between 2010 and 2026, OrganiGram Holdings, Net Receivables quarterly trend regression had mean deviation of  22,663,714 and range of 78.3 M. View All Fundamentals
 
Net Receivables  
First Reported
2011-09-30
Previous Quarter
64.9 M
Current Value
49.9 M
Quarterly Volatility
17.4 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check OrganiGram Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OrganiGram Holdings' main balance sheet or income statement drivers, such as Interest Expense of 303.5 K, Selling General Administrative of 67.4 M or Other Operating Expenses of 301.3 M, as well as many indicators such as Price To Sales Ratio of 2.86, Dividend Yield of 0.0 or PTB Ratio of 0.82. OrganiGram financial statements analysis is a perfect complement when working with OrganiGram Holdings Valuation or Volatility modules.
  
Build AI portfolio with OrganiGram Stock
Check out the analysis of OrganiGram Holdings Correlation against competitors.
For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.
The Net Receivables trend for OrganiGram Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether OrganiGram Holdings is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest OrganiGram Holdings' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of OrganiGram Holdings over the last few years. It is OrganiGram Holdings' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OrganiGram Holdings' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

OrganiGram Net Receivables Regression Statistics

Arithmetic Mean22,684,087
Geometric Mean2,658,252
Coefficient Of Variation122.35
Mean Deviation22,663,714
Median11,632,000
Standard Deviation27,754,706
Sample Variance770.3T
Range78.3M
R-Value0.90
Mean Square Error158.8T
R-Squared0.81
Slope4,936,792
Total Sum of Squares12325.2T

OrganiGram Net Receivables History

202678.3 M
202574.6 M
202464.9 M
202337.2 M
202227.5 M
202146.4 M
202021 M

About OrganiGram Holdings Financial Statements

Investors use fundamental indicators, such as OrganiGram Holdings' Net Receivables, to determine how well the company is positioned to perform in the future. Although OrganiGram Holdings' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Receivables74.6 M78.3 M

Currently Active Assets on Macroaxis

When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:
Check out the analysis of OrganiGram Holdings Correlation against competitors.
For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is there potential for Pharmaceuticals market expansion? Will OrganiGram introduce new products? Factors like these will boost the valuation of OrganiGram Holdings. Anticipated expansion of OrganiGram directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.11
Revenue Per Share
2.105
Quarterly Revenue Growth
0.487
Return On Assets
(0.01)
Return On Equity
0.0464
Investors evaluate OrganiGram Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating OrganiGram Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause OrganiGram Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between OrganiGram Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OrganiGram Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, OrganiGram Holdings' market price signifies the transaction level at which participants voluntarily complete trades.